A PHASE IIIb OPEN-LABEL, SINGLE-ARM STUDY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TO EVALUATE THE USABILITY OF RANIBIZUMAB 10 mg/0.1 mL PREFILLED SYRINGE WITH THE PORT DELIVERY SYSTEM